1. Michael A. Mussallem Chairman and CEO Edwards Lifesciences Leading the fight against advanced cardiovascular disease

2. Edwards History Founded by Miles “Lowell” Edwards in 1958Founded by Miles “Lowell” Edwards in 1958 – Inventor and visionary, held 60+ patents Partnered with physicians to introduce breakthrough medical devices to the worldPartnered with physicians to introduce breakthrough medical devices to the world Changes in ownershipChanges in ownership – 1958Edwards Laboratories – 1968American Hospital Supply Corp. – 1984Baxter International Inc. – 2000Edwards Lifesciences (NYSE:EW)

3. Edwards Leads Growth Industry A leader in treating advanced cardiovascular diseaseA leader in treating advanced cardiovascular disease –Cardiovascular disease is progressive; leading killer and health expense 2007 Sales: $1.091 billion2007 Sales: $1.091 billion –2008 projected sales ~ $1.2+ billion Broad global presenceBroad global presence –Products sold in ~100 countries –5,600+ employees World’s Leading Killers 2007 Sales By Region

4. St.-Prex, Switzerland Horw, Switzerland Añasco, Puerto Rico Irvine Salt Lake City Mississauga, Canada Haina, Dominican Republic Sao Paulo, Brazil Mumbai, India Tokyo, Japan Edwards’ Global Operations Singapore 40+ offices in 35 countries

5. Edwards’ Robust Core Businesses 90% of sales from products with #1 global positions90% of sales from products with #1 global positions –Leader in heart valve therapy –Leader in hemodynamic monitoring High barriers to entryHigh barriers to entry Strong brand recognitionStrong brand recognition Trusted partner with leading cliniciansTrusted partner with leading clinicians Strong base from which innovation can flourishStrong base from which innovation can flourish 2007 Global Heart Valve Sales* *Estimated 2007 Global Hemodynamic Monitoring Sales* $435 million $1.1 billion

6. Edwards’ Global Strategy A patient focusA patient focus –Targeted populations are large and growing –Cardiovascular disease remains the leading cause of death and largest healthcare expense Sizable growth opportunitiesSizable growth opportunities –Targeting transformational technologies in Structural Heart Disease and Critical Care Medicine A product leadership strategyA product leadership strategy –Clinical superiority remains our primary basis of differentiation and competitive advantage

7. Global Challenges/Opportunities Business practice scrutinyBusiness practice scrutiny Reimbursement pressureReimbursement pressure Regulatory timelinesRegulatory timelines Global and local competitorsGlobal and local competitors Price transparencyPrice transparency

8. Helping Patients is Our Life’s Work, and